Officials note it could slow acquisition of physicians’ offices, but hospitals bristle at prospect.
This article was originally published on Medical Economics®.
Medicare reimbursement rates based on location could change under a policy recommended for a vote in Congress.
MedPAC, the independent Medicare Payment Advisory Commission, this week published its annual report with a recommendation on “aligning fee-for-service payment rates across ambulatory settings.” It’s a move that could drive down patient costs while saving money for Medicare.
The Medicare Payment Advisory Commission has recommended site neutral reimbursement, a topic that has sparked debate within the health care industry.
It could also bolster independent physician practices by removing a financial incentive for hospitals to acquire them and bill for services at a higher rate, the report said. The committee cited “recent growth in hospital acquisition of physician practices” as a specific reason for the recommendation.
Also known as site-neutral policies or reimbursement, the issue has sparked debate within the health care industry. The American Academy of Family Physicians and the American College of Physicians both are part of the Alliance for Site Neutral Payment Reform, a coalition of “patient advocates, providers, payers, and employers who support payment parity” regardless of location.
Meanwhile, the American Hospital Association (AHA) said the MedPAC recommendation would redistribute $7.5 billion in Medicare spending for some services performed in outpatient departments and ambulatory surgical centers. That would cut Medicare spending by 2.5% for rural hospitals, reducing their average total Medicare margin from –17.8% to –21%, leading “to devastating financial hardship, even more closures and drastically impact the communities rural hospitals serve.”
AHA argued hospitals are held to higher standards that ASCs and physician offices. Along with 24/7 emergency department services, hospitals offer specialized medical capabilities such as burn and maternity wards, and must pay for everything from disaster preparedness to fire drills.
Meanwhile, hospitals are struggling to bounce back from the COVID-19 pandemic, “the most significant health crisis in a century,” according to AHA.
Ashley Thompson, AHA senior vice president of public policy and analysis, spoke on the issue in an April 26, 2023, hearing of the Health Subcommittee of the U.S. House of Representatives’ Energy & Commerce Committee.
“Now more than ever, hospitals need stable and adequate reimbursements as they face challenging financial circumstances,” Thompson said.
No one denies the crucial role of hospitals in communities, said Rep. Cathy McMorris Rodgers, R-Washington, Energy & Commerce Committee chairwoman, who spoke in the same hearing. She cited procedures such as drug administration, diagnostic tests, and imaging that can be done safely in physician offices, and in hospitals.
“This is the right thing to do for patients,” Rodgers said. “Let’s be clear: Hospitals are integral parts of our communities, and we recognize the effects of high labor costs, inflation, and ever-increasing government regulation.
“But the question before us is: Should we support hospitals through a complex and opaque network of cross-subsidies with unintended consequences, like consolidation, that increase costs for patients? Or do we separately work on a transparent, accountable way to support hospitals that need it?”
MedPAC also recommended:
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More
Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans
February 10th 2025This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Read More